Abstract: The purpose of the present invention is to provide novel complexes that improve the effect of nucleic acid medicines. Provided is a complex in which a multibranched lipid(s) binds through a linker to a strand of an oligonucleotide comprising a nucleic acid medicine having suppressing activity of the target gene expression.

Abstract: The invention relates to polynucleotide agents, e.g., antisense polynucleotide agents, targeting an angiotensinogen (AGT) gene, and methods of using such polynucleotide agents to inhibit expression of AGT and to treat subjects having an AGT-associated disease, e.g., hypertension.

Abstract: The present invention provides a pentosan polysulfate having a uronic acid content of 7.0 mass % to 15.0 mass % and an acetyl group content of 0 mass % to 2.0 mass %; a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable solvate of the pentosan polysulfate or of the pharmaceutically acceptable salt thereof. The pentosan polysulfate, the pharmaceutically acceptable salt thereof, or the pharmaceutically acceptable solvate of the pentosan polysulfate or of the pharmaceutically acceptable salt thereof are useful as an active ingredient of a medicament for preventing and/or treating a disease caused by abnormal enhancement of FGF-2 function, and as a pH buffer agent.

Abstract: The present application provides a composition for improving a symptom of spine/spinal cord injury in a subject, the composition comprising molecular hydrogen as an active ingredient; and a method for improving a symptom of spine/spinal cord injury in a subject, the method comprising administering the composition to the subject.

Abstract: Described herein are methods of treating pulmonary hypertension by maintaining dosing frequency and/or minimizing skipped breaths during pulsed administration of inhaled nitric oxide.

Abstract: Neuroprotective preparations (formulations) employing the synergistic, neurotrophic benefits of nutritional lithium with bioavailable magnesium (FIG. 1). The biological synergism of lithium and magnesium is further enhanced with a proprietary base of synergistic, neurotrophic nutrients. A highly-effective, trans-mucosal, delivery system is included to provide exceptional bioavailability of a palatable, convenient intra-oral preparation, which saturates the vascular tissue in the oral cavity for efficient absorption.

Abstract: This invention is directed to methods for prevention of infections by highly pathogenic viruses by applying to the nasal mucous membranes topical preparations comprising the broad-spectrum antimicrobial agent povidone-iodine.

Abstract: The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets.

Abstract: The present invention provides an anticancer agent that is readily absorbed into cells but is not chemically altered and does not induce immunity when metabolized inside an organism and that can be used in combination with other anticancer agents. As the result of diligent research, the inventors of the present invention discovered de novo that ozone water than can be preserved for a long time has anticancer activity. It was also found that the effect of the ozone water was greatly increased when the ozone water was used in combination with existing anticancer agents.

Abstract: The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of 1.0-2.8 mM, is sterile and has a pH of 6.5-7.6. The present invention further relates to a method for producing the medical solution and the use thereof.

Abstract: A modified T cell is described which is adapted to overexpress SLC1A5, an isoform of SLC1A5 or an alternative tryptophan or glutamine transporter. Further described is the use of such modified T cells in the treatment of disease, in particular cancer, methods to select modified T cells which overexpress SLC1A5 and nucleic acids and vectors to provide for such modified T cells.

Abstract: The present invention relates generally to immunotherapy for the treatment or prevention of HIV. In particular, the disclosure provides lentiviral vectors and associated methods that are optimized to treat HIV without a pre-immunization step.

Abstract: The subject matter disclosed herein is generally directed to compositions and methods for treating diffuse gliomas with histone H3 lysine27-to-methionine mutations (H3K27M-gliomas). Disclosed herein are gene signatures specific for tumor cell types and compositions for treatment of H3K27M gliomas. In one embodiment, PRC1 is targeted in a treatment regimen for H3K27M-gliomas.

Abstract: The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19.

Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.

Abstract: The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells and/or CD8+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for pooling enriched CD4+ and CD8+ cells, such as at a 1:1 ratio, and then incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.

Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.

Abstract: The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.

Abstract: The present invention relates to a method for selecting a cell or a virus expressing on its surface an antigen-binding protein specifically binding to a protein antigen of interest (PAI) while counter selection using a similar protein antigen (SPA) is applied. Further, the invention provides a method for determining the sequence of a nucleic acid encoding an antigen-binding protein or an antigen-binding part thereof and a method for producing a cell expressing a nucleic acid encoding an antigen-binding protein or an antigen-binding part thereof. The invention also relates to a method for treating a subject with a selected cell population.

Abstract: The present invention relates to modified immune cells or precursors thereof, comprising dual (a first and a second) chimeric receptors (e.g. CARs). One aspect includes a first CAR comprising a 4-1BB intracellular domain and a second CAR comprising a CD28 intracellular domain. Another aspect includes a method for treating of an HIV infected mammal using a modified T cell comprising a first CD4 CAR comprising a 4-1BB intracellular domain and a second CD4 CAR comprising a CD28 intracellular domain.

Abstract: Provided herein are chimeric transmembrane receptors and methods of using them to regulate selective gene expression in cells (e.g., immune cells). For example, chimeric transmembrane receptors provided herein may be synthetic receptor-like protein tyrosine phosphatases (“synPTPRs”) that can regulate transcription of a heterologous target gene in a cell when bound by a target antigen present on a target cell.

Abstract: Provided are engineered cells for adoptive therapy, including NK cells and T cells. Also provided are compositions for engineering and producing the cells, compositions containing the cells, and methods for their administration to subjects. In some embodiments, the cells contain genetically engineered antigen receptors that specifically bind to antigens, such as chimeric antigen receptors (CARs) and costimulatory receptors. In some embodiments, the cells include receptors targeting multiple antigens. In some embodiments, the cells include repression of one or more gene product, for example, by disruption of a gene encoding the gene product. In some embodiments, a gene encoding an antigen recognized by the engineered antigen receptor is disrupted, reducing the likelihood of targeting of the engineered cells. In some embodiments, the antigen recognized by the engineered antigen receptor is related to a tumor antigen recognized by the engineered antigen receptor.

Abstract: Provided is a method for gene editing of an enhancer site of the BCL11A in hematopoietic stem cells. The genetically modified hematopoietic stem cells have the functions of normal cells, and can significantly increase the expression of fetal hemoglobin so as to be used in the treatment of ? thalassemia and sickle cell anemia.

Abstract: Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.

Abstract: The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.

Abstract: Disclosed is a composition for prevention, treatment or ameliorating of atopic dermatitis, the composition containing a monoclonal stem cell obtained via improved subfractionation culturing of a stem cell, a preparation method thereof, and a method for treating atopic dermatitis using the same. According to the improved subfractionation culturing and proliferation method of the stem cell, a desired amount of the monoclonal stem cells may be obtained in a massive manner in a short time via the rapid proliferation of the monoclonal stem cell. The monoclonal mesenchymal stem cell as obtained has an enhanced effect of treatment, prevention or ameliorating of atopic dermatitis, and thus may be usefully used for an atopic dermatitis treatment agent.

Abstract: The present invention relates to a medium composition for cell proliferation, skin regeneration, and wrinkle improvement that contains a conditioned medium of pluripotent stem cells (PSCs), neural stem cells (NSCs), and embryonic fibroblasts (FBs) as cells isolated from avian eggs as an active ingredient. Specifically, the conditioned medium of egg cells can fundamentally block contamination due to the use of animal serums, exhibits a proliferation effect of various cells containing human stem cells and skin cells without the possibility of transmission by infectious agents between heterogeneous species due to the use of support cells, and exhibits significant skin regeneration or wrinkle improvement effects, and thus the conditioned medium of egg cells can be usefully used for a medium composition for cell proliferation and a cosmetic composition for skin regeneration or wrinkle improvement.

Abstract: Provided herein are methods and compositions related to treating or preventing seizures. In some aspects, provided herein are methods of treating or preventing seizures in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

Abstract: Provided are Megamonas funiformis and applications thereof. Specifically, the Megamonas funiformis has the effects for preventing and/or treating inflammation-related diseases, such as inflammatory bowel diseases (such as ulcerative enteritis, gastritis, and general enteritis) and cardiovascular diseases.

Abstract: Provided are uses of Bacteroides fragilis and a therapeutic or prophylactic composition containing Bacteroides fragilis in the treatment and/or prevention of tumors. Also provided are uses of Bacteroides fragilis and a composition containing Bacteroides fragilis in the preparation of a medicament for the treatment and/or prevention of tumors, which can significantly inhibit the growth of tumors. Also provided are uses of Bacteroides fragilis in the preparation of pharmaceutical compositions, foodstuffs, health products and food additives for the treatment and/or prevention of tumors.

Abstract: Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of 3?-SL and/or 6?-SL, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the spray-dried powder.

Abstract: Tributyrin and/or tributyrin derivatives are used to selectively increase the levels of Bifidobacteria in the gut. In preferred methods, the tributyrin and/or tributyrin derivatives are orally administered alone or in combination with a food item or other nutritionally acceptable carrier, and may further include Bifidobacteria. Tributyrin-enhanced Bifidobacterium strains are also contemplated that include Bifidobacteria previously cultured in tributyrin and/or tributyrin derivatives.

Abstract: Tributyrin and/or tributyrin derivatives are used to selectively increase the levels of Bifidobacteria in the gut. In preferred methods, the tributyrin and/or tributyrin derivatives are orally administered alone or in combination with a food item or other nutritionally acceptable carrier, and may further include Bifidobacteria. Tributyrin-enhanced Bifidobacterium strains are also contemplated that include Bifidobacteria previously cultured in tributyrin and/or tributyrin derivatives.

Abstract: Provided is a method of detecting presence or absence of a functional gastrointestinal disorder by measuring bacteria occupancy within a human stomach.

Abstract: A horizontal axis rotary separation apparatus is deployed in a process for separating resinous trichomes rich in flavoring, aromatic and/or medicinal components produced in plant trichome glands from unwanted plant matter. The process physically separates resin rich beads at the trichome gland head from extraneous plant matter by one or move separation sieves. The sieves are provided in or as a casing over a rigid frame member. The sieves are mesh fabric bags or screen that are easily opened and replenished in a batch operating mode, and are removable from the frame for cleaning and maintenance. Other aspects of the invention include processes that improve process efficiency and speed, and yield products of superior quality.

Abstract: Disclosed in the present disclosure is a composition for improving skin damage caused by fine dust, which contains an Aureobasidium pullulans strain; a lysate thereof; a culture thereof; or an extract of the strain, the lysate or the culture as an active ingredient, and the composition has an effect of promoting the expression of keratinocyte differentiation markers and granular layer tight junction markers, thereby enhancing the skin barrier function and having skin-moisturizing, anti-aging and wrinkle-suppressing effects, and, thus, has an excellent effect in terms of improving skin damage caused by fine dust.

Abstract: A method of making a dietary supplement includes the steps of mixing together, to define a mixture, refined avocado oil, ground Cannabis indica having a deactivated THC content of 15% to 21%, ground mixture of Cannabis sativa and Cannabis indica having a THC content of 20% to 30%, and ground mixture of Cannabis sativa and Cannabis indica containing a THC content of less than 6% and a CBD content of between 18% and 30%. Heating the mixture and then straining the mixture through a fine mesh strainer to define retained oil.

Abstract: The disclosed invention generally relates to pharmaceutical compounds and methods for treating and/or preventing diseases and disorders that often manifest in hyper and/or hypokinetic movements symptoms, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids to subjects in need of treatment. The disclosed invention further relates to cannabinoid pharmaceutical compounds where said compound contains at least some non-cannabinoid components.

Abstract: The disclosed invention generally relates to pharmaceutical compounds and methods for treating and/or preventing diseases and disorders that often manifest in hyper and/or hypokinetic movements symptoms, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids to subjects in need of treatment. The disclosed invention further relates to cannabinoid pharmaceutical compounds where said compound contains at least some non-cannabinoid components.

Abstract: The present disclosure relates to methods of enriching root powder products, for example beetroot powder. In particular, the methods relates to increasing the nitrate content and/or reducing the sugar content of the root powder product. The disclosure also relates to root powder products with increased with at least 3% nitrate.

Abstract: Formulations and methods for treating inflammation using pitcher plants are described herein. The pitcher plant is made into herbal preparations, such as tinctures and infused solutions. The herbal preparation of the pitcher plant can be combined with vitamins, minerals, glutathione, solutions, and other plant preparations, such as a hemp plant preparation containing cannabidiol, to make a topical formulation. Administering the formulation to a subject can reduce and treat inflammation.

Abstract: An orally administrable composition for treating or reducing damage to connective tissue or for treating or reducing inflammatory symptoms associated with damage to connective tissue includes a synergistic combination of: (i) avocado/soybean unsaponifiables; and (ii) lipoic acid, or a salt or derivative thereof. Methods for treating or reducing damage to connective tissue, for treating or reducing inflammatory symptoms associated with damage to connective tissue, or for reducing levels of one or more inflammatory mediators in connective tissue include administering the orally administrable composition to an avian or mammalian subject.

Abstract: The invention relates to ophthalmic compositions containing an aqueous extract derived from Polygonum cuspidatum Sieb. et Zucc. and/or an aqueous extract derived from Prunella vulgaris. The invention further relates to the use of the ophthalmic compositions in the treatment of myopia.

Abstract: Disclosed is a combination of extracts of Cynara cardunculus and Citrus bergamia which are useful for the prevention and treatment of hepatic steatosis and other disorders correlated with dyslipidaemic conditions.

Abstract: Disclosed are compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or dermatologic skin conditions. The compositions include black willow bark extract, cats claw extract, and dragon's blood extract. The compositions ameliorate skin conditions including acne, rosacea, blemish, dermatitis, eczema, or the like.

Abstract: Provided are a pharmaceutical composition for preventing an alcoholic hangover or alleviating a hangover, comprising a Longan arillus extract as an active ingredient, and a food composition for alleviating a hangover, comprising a Longan arillus extract.

Abstract: The present invention relates to a composition for enhancing immunity or a composition for preventing or ameliorating neurodegenerative diseases, both of which contain, as an active ingredient, a mixture extract of goji berries, mulberries and jujubes or an extract mixture thereof.

Abstract: Disclosed in the present application are: a composition containing a green tea extract comprising at least one selected from the group consisting of 7 wt % or more of polysaccharides, less than 20 wt % of catechins, and 10 wt % or more of dietary fibers, relative to a total weight of the green tea extract, the composition having a use for blood glucose control; and a method for preparing the composition. The composition has not only effects of inhibiting activity of glucosidase and amylase but also effects of lowering blood glucose by inhibiting the glucose uptake in small intestinal cells.

Abstract: The present invention discloses a composition comprising Allium sativum extract standardized to contain not less that 0.3% w/w S-allylcysteine, Beta vulgaris extract standardized to contain not less than 2% w/w nitrates, Nigella sativa extract standardized to contain 0.1%-5% w/w thymoquinone, about 0.01%-10% w/w thymohydroquinone, about 20%-95% w/w fatty acids, about 0.001%-3% w/w ?-hederin or hederagenin, and Terminalia arjuna extract standardized to contain 3% w/w arjunoglucosides for use a prostaglandin transporter inhibitor. The invention also discloses the use of the aforementioned composition in the therapeutic management of hypertension and cardiovascular complications.